AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29357902 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT with 20Gy in five fractions and SIB to 30Gy in five fractions
Number of subjects: 120
Study 29357902 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 27224066 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue® Oasys® for Presbyopia (AOP)
Number of subjects: 42
Study 27224066 — intervention group
Group type: EXPERIMENTAL
Intervention: Air Optix® Aqua Multifocal (AOMF)
Number of subjects: 42
Study 27224066 — intervention group
Group type: COMPARATOR
Intervention: Air Optix® Aqua Single Vision (AOSV)
Number of subjects: 42
Study 24060806 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (2-hour faculty lecture on cultural competence and student group presentation)
Number of subjects: 146
Study 24060806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 146
Study 22917599 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention consisting of manual tooth/gum brushing, 0.12% chlorhexidine oral rinse administered twice daily by nurses, and upright feeding positioning at meals.
Number of subjects: 0
Study 22917599 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned in the abstract.
Number of subjects: 0
Study 19955007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ideal self attributes
Number of subjects: 80
Study 19955007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ought self attributes
Number of subjects: 80
Study 19955007 — intervention group
Group type: EXPERIMENTAL
Intervention: Feared self attributes
Number of subjects: 80
Study 19955007 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability
Number of subjects: 80
Study 19955007 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 80
Study 18158427 — intervention group
Group type: EXPERIMENTAL
Intervention: NESS L300 neuroprosthesis
Number of subjects: 24
Study 17066294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapeutic advisory intervention
Number of subjects: 300
Study 17066294 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 300
Study 12828058 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar cutter (thermal device)
Number of subjects: 20
Study 12828058 — intervention group
Group type: COMPARATOR
Intervention: Harmonic scalpel (non-thermal device)
Number of subjects: 20
Study 10714046 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine plus CBT
Number of subjects: 63
Study 10714046 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus CBT
Number of subjects: 63
Study 8885912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate, 2.5 mg/day for 5 days
Number of subjects: 60
Study 8885912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1417466 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 21
Study 1417466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 3927339 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 13
Study 3927339 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg amphetamine sulfate
Number of subjects: 13
Study 31326043 — intervention group
Group type: EXPERIMENTAL
Intervention: Bass Intrasulcular Technique (BIT)
Number of subjects: 48
Study 31326043 — intervention group
Group type: COMPARATOR
Intervention: Control group (NI) with no brushing technique instructions
Number of subjects: 48
Study 29467335 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL containing apoE but not apoCIII
Number of subjects: 1967
Study 29467335 — intervention group
Group type: COMPARATOR
Intervention: HDL containing apoCIII
Number of subjects: 1967
Study 27153927 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematocrit normalization (Hct 42%)
Number of subjects: 27
Study 27153927 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (at Hct 30% and Hct 42%)
Number of subjects: 27
Study 27153927 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Hct normalization and exercise training
Number of subjects: 27
Study 27153927 — intervention group
Group type: COMPARATOR
Intervention: Untrained phase at Hct 30%
Number of subjects: 27
Study 27153927 — intervention group
Group type: COMPARATOR
Intervention: Untrained phase at Hct 42%
Number of subjects: 27
Study 24758417 — intervention group
Group type: EXPERIMENTAL
Intervention: KRG root (3 g)
Number of subjects: 16
Study 24758417 — intervention group
Group type: EXPERIMENTAL
Intervention: KRG ginsenosides extract
Number of subjects: 16
Study 24758417 — intervention group
Group type: EXPERIMENTAL
Intervention: KRG polysaccharides extract
Number of subjects: 16
Study 24758417 — intervention group
Group type: COMPARATOR
Intervention: Cornstarch control
Number of subjects: 16
Study 22428474 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber Band Ligation (RBL)
Number of subjects: 75
Study 22428474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Hemorrhoidal Radiocoagulation (CHR)
Number of subjects: 75
Study 20626209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (1 g twice daily)
Number of subjects: 1262
Study 20626209 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin (2.5-4 mg/kg/day)
Number of subjects: 1262
Study 20626209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1262
Study 20626209 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 1262
Study 20626209 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 1262
Study 18494959 — intervention group
Group type: EXPERIMENTAL
Intervention: Larval therapy ('bagged' and 'loose')
Number of subjects: 35
Study 18494959 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (hydrogel)
Number of subjects: 35
Study 16437318 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular physical exercise (supervised aerobic exercise program for four months)
Number of subjects: 11
Study 16437318 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 age- and sex-matched healthy persons who did not exercise regularly)
Number of subjects: 11
Study 12913770 — intervention group
Group type: EXPERIMENTAL
Intervention: S. sonnei-CRM(9)
Number of subjects: 80
Study 12913770 — intervention group
Group type: EXPERIMENTAL
Intervention: S. flexneri 2a-rEPA(succ)
Number of subjects: 80
Study 12913770 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 80
Study 10384400 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7796089 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 50 mg/kg intravenous infusion in saline
Number of subjects: 18
Study 7796089 — intervention group
Group type: COMPARATOR
Intervention: Quinine plus intravenous saline (Control)
Number of subjects: 18
Study 7796089 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 18
Study 7796089 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) and Control
Number of subjects: 18
Study 2109477 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexital (100 mg induction, 10 mg.min‐1 maintenance)
Number of subjects: 0
Study 2109477 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (15 mg induction, 0.1 mg.min‐1 maintenance) + Flumazenil (0.53 mg mean dose)
Number of subjects: 0
Study 7356888 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine treatment for 4 weeks
Number of subjects: 20
Study 7356888 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 patients after treatment only)
Number of subjects: 20
Study 31575509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamrevlumab 30 mg/kg every 3 weeks for 48 weeks (16 infusions)
Number of subjects: 103
Study 31575509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 31575509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Number of subjects: 103
Study 31201796 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 28
Study 27906757 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive preoperative VR experience
Number of subjects: 127
Study 27906757 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative experience
Number of subjects: 127
Study 26343698 — intervention group
Group type: EXPERIMENTAL
Intervention: PUFA supplementation (1.3 g of PUFA and 10 mg of vitamin E daily for 12 weeks)
Number of subjects: 53
Study 26343698 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 mg of vitamin E daily for 12 weeks)
Number of subjects: 53
Study 23068021 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 149
Study 23068021 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 149
Study 21484037 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (6 exercises, 3 sets of 12, 10 and 8 reps, perceived exertion 11 to 13 on the Borg scale)
Number of subjects: 8
Study 21484037 — intervention group
Group type: COMPARATOR
Intervention: Control session (resting on exercise machines)
Number of subjects: 8
Study 19466963 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SSZ) and Pentoxifylline (PTX)
Number of subjects: 64
Study 19466963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 16340949 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (OFS) 8 g twice daily (16 g/day)
Number of subjects: 10
Study 16340949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrine maltose (DM)) 8 g twice daily (16 g/day)
Number of subjects: 10
Study 15545348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum meal composition
Number of subjects: 0
Study 15545348 — intervention group
Group type: COMPARATOR
Intervention: National Cholesterol Education Program Step I diet
Number of subjects: 0
Study 15545348 — intervention group
Group type: COMPARATOR
Intervention: National Cholesterol Education Program Step II diet
Number of subjects: 0
Study 11006176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical sequential norethisterone (NET)-based HRT with continuous 2 mg oral oestradiol valerate for three cycles
Number of subjects: 0
Study 11006176 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone-based HRT regimens (0.05, 0.1, 0.25 and 0.5 mg/day from day 15-28 for six treatment cycles)
Number of subjects: 0
Study 11006176 — intervention group
Group type: COMPARATOR
Intervention: Natural cycle (control samples)
Number of subjects: 0
Study 9248777 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of mirtazapine in the fasting state
Number of subjects: 19
Study 9248777 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of mirtazapine after a high-fat meal
Number of subjects: 19
Study 7714224 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 22
Study 7714224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 2707980 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary nursing
Number of subjects: 90
Study 2707980 — intervention group
Group type: COMPARATOR
Intervention: Team nursing
Number of subjects: 90
Study 740581 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen (ethynodiol diacetate 9 microgram/day)
Number of subjects: 0
Study 740581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen (mestranol 0.9 microgram/day)
Number of subjects: 0
Study 740581 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with oestrogen and progestogen
Number of subjects: 0
Study 740581 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen in preliminary human study
Number of subjects: 0
Study 31965830 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal anxiety at baseline
Number of subjects: 108
Study 31965830 — intervention group
Group type: EXPERIMENTAL
Intervention: High pain self‐efficacy
Number of subjects: 108
Study 31965830 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophizing
Number of subjects: 108
Study 31965830 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of movement
Number of subjects: 108
Study 31965830 — intervention group
Group type: EXPERIMENTAL
Intervention: Life satisfaction
Number of subjects: 108
Study 31965830 — intervention group
Group type: EXPERIMENTAL
Intervention: Low number of comorbidities
Number of subjects: 108
Study 31709560 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-case intervention randomization procedures
Number of subjects: 0
Study 31709560 — intervention group
Group type: EXPERIMENTAL
Intervention: Excel-based software package for randomization
Number of subjects: 0
Study 28724186 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% topical formulation of InsP6 applied once a day
Number of subjects: 20
Study 28724186 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid gel (control)
Number of subjects: 20
Study 28724186 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% topical formulation of InsP6
Number of subjects: 20
Study 26237326 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 323
Study 26237326 — intervention group
Group type: COMPARATOR
Intervention: Standard Methadone Care (Control)
Number of subjects: 323
Study 24634205 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) 8 mg/kg every 2 weeks
Number of subjects: 67
Study 23098097 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemorrhoidal artery ligation (HAL)
Number of subjects: 350
Study 23098097 — intervention group
Group type: COMPARATOR
Intervention: Rubber band ligation (RBL)
Number of subjects: 350
Study 19264143 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive EEG recordings
Number of subjects: 0
Study 19264143 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive EEG recordings
Number of subjects: 0
Study 17888460 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA‐A/benzodiazepine receptor inverse agonist selective for the alpha5 subtype (a5IA)
Number of subjects: 0
Study 17888460 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (mean breath concentration 150mg/100ml)
Number of subjects: 0
Study 15073706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-clamp applied only to the aorta (Group 1)
Number of subjects: 22
Study 15073706 — intervention group
Group type: COMPARATOR
Intervention: Cross-clamp applied to both the aorta and pulmonary artery (Group 2)
Number of subjects: 22
Study 11234776 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.3 mg, i.v.)
Number of subjects: 0
Study 11234776 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (0.2 mg, i.v.)
Number of subjects: 0
Study 9587372 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative pelvic external irradiation
Number of subjects: 0
Study 8385525 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10mg once daily
Number of subjects: 0
Study 8385525 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10mg once daily
Number of subjects: 0
Study 3097109 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg)
Number of subjects: 51
Study 3097109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 3097109 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (in open trial)
Number of subjects: 51
Study 29505689 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS treatment
Number of subjects: 36
Study 29505689 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS placebo
Number of subjects: 36
Study 29505689 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 26867697 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based diet and exercise intervention
Number of subjects: 194
Study 26867697 — intervention group
Group type: COMPARATOR
Intervention: Control group (diet and exercise intervention without mindfulness)
Number of subjects: 194
Study 25231730 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Ca group (actual Ca intake: 1243 mg/d)
Number of subjects: 220
Study 25231730 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-Ca group (actual Ca intake: 985 mg/d)
Number of subjects: 220
Study 25231730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca supplementation
Number of subjects: 220
Study 22664798 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 30 mg QD
Number of subjects: 536
Study 22664798 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 45 mg QD
Number of subjects: 536
Study 22664798 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg QD
Number of subjects: 536
Study 22664798 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 536
Study 19520690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab plus PDT using a light dose of 25 J/cm2 (group 1)
Number of subjects: 36
Study 19520690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab plus PDT using a light dose of 12 J/cm2 (group 2)
Number of subjects: 36
Study 19520690 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal bevacizumab plus sham PDT (group 3)
Number of subjects: 36
Study 17671809 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 177
Study 17671809 — intervention group
Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 177
Study 14963719 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone solution (0.4 mg/ml)
Number of subjects: 25
Study 14963719 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 25
Study 11888583 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and lamivudine
Number of subjects: 183
Study 11888583 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and abacavir
Number of subjects: 183
Study 11888583 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine and abacavir
Number of subjects: 183
Study 11888583 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 183
Study 11888583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study 10207641 — intervention group
Group type: EXPERIMENTAL
Intervention: Education plus counseling (E + C)
Number of subjects: 298
Study 10207641 — intervention group
Group type: COMPARATOR
Intervention: Standard education model
Number of subjects: 298
Study 10207641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (E + C and Standard education)
Number of subjects: 298
Study 8652254 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiotape of a previous consultation (n = 63)
Number of subjects: 117
Study 8652254 — intervention group
Group type: COMPARATOR
Intervention: No audiotape (Control group, n = 54)
Number of subjects: 117
Study 2073774 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner-written invitations to attend screening mammography
Number of subjects: 0
Study 2073774 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner-written invitations with an appointment
Number of subjects: 0
Study 2073774 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner-written invitations without an appointment
Number of subjects: 0
Study 2073774 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder letters sent to nonrespondents who had attended the practice in the previous 12 months
Number of subjects: 0
Study 2073774 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reminder letter)
Number of subjects: 0
Study 7271298 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (2-year course)
Number of subjects: 252
Study 7271298 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 252
Study 31857198 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity cycling for 17 min
Number of subjects: 50
Study 31857198 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling for 17 min
Number of subjects: 50
Study 31857198 — intervention group
Group type: COMPARATOR
Intervention: Minimal-intensity cycling for 17 min
Number of subjects: 50
Study 31512682 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-working students
Number of subjects: 298
Study 31512682 — intervention group
Group type: COMPARATOR
Intervention: Working students
Number of subjects: 298
Study 28294697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (1064 nm)
Number of subjects: 46
Study 28294697 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm)
Number of subjects: 46
Study 28294697 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 46
Study 26459273 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen with glargine once daily and glulisine before meals
Number of subjects: 72
Study 26459273 — intervention group
Group type: COMPARATOR
Intervention: Premixed human insulin (30% regular insulin and 70% NPH insulin) twice daily
Number of subjects: 72
Study 26459273 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen
Number of subjects: 72
Study 26459273 — intervention group
Group type: COMPARATOR
Intervention: Premixed human insulin
Number of subjects: 72
Study 23465334 — intervention group
Group type: EXPERIMENTAL
Intervention: High parental investment
Number of subjects: 0
Study 23465334 — intervention group
Group type: COMPARATOR
Intervention: Low parental investment
Number of subjects: 0
Study 23465334 — intervention group
Group type: COMPARATOR
Intervention: Low-risk children
Number of subjects: 0
Study 21795430 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium doses ≥1000 mg
Number of subjects: 54
Study 21795430 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium dose of 800 mg
Number of subjects: 54
Study 19252156 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 811
Study 19252156 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 811
Study 17846069 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental speed-dependent treadmill training
Number of subjects: 54
Study 17846069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 54
Study 15506570 — intervention group
Group type: EXPERIMENTAL
Intervention: Single question screening approach
Number of subjects: 2800